Table 4.
Tofacitinib versus tocilizumab: comparison of CDAI-based improvements at 12 months in patients with RA after propensity score matching
| bDMARD-naïve patients with RA | Previous bDMARD-failure patients with RA | |||||||
| Unadjusted OR* (95% CI) | P value | Adjusted OR* (95% CI) | P value | Unadjusted OR* (95% CI) | P value | Adjusted OR* (95% CI) | P value | |
| Remission (CDAI≤2.8) | 3.33 (1.75 to 6.35) | <0.001 | 3.31 (1.69 to 6.48) | <0.001 | 0.83 (0.36 to 1.93) | 0.67 | 0.77 (0.32 to 1.86) | 0.56 |
| Remission or low CDAI (≤10) | 2.00 (0.97 to 4.12) | 0.061 | 2.05 (0.93 to 4.52) | 0.076 | 1.88 (1.04 to 3.39) | 0.035 | 1.67 (0.90 to 3.12) | 0.11 |
| CDAI85† (major response) | 4.10 (2.05 to 8.18) | <0.001 | 3.88 (1.87 to 8.03) | <0.001 | 0.77 (0.37 to 1.57) | 0.47 | 0.65 (0.29 to 1.45) | 0.29 |
| CDAI70† (moderate response) | 3.18 (1.62 to 6.26) | <0.001 | 2.89 (1.43 to 5.84) | 0.003 | 1.05 (0.56 to 1.97) | 0.87 | 0.96 (0.49 to 1.88) | 0.90 |
| CDAI50† (minor response) | 1.69 (0.85 to 3.36) | 0.13 | 1.56 (0.76 to 3.21) | 0.22 | 1.44 (0.79 to 2.63) | 0.23 | 1.32 (0.70 to 2.48) | 0.39 |
| MCID-based improvement‡ | 1.69 (0.85 to 3.36) | 0.13 | 1.56 (0.76 to 3.21) | 0.22 | 1.67 (0.93 to 2.99) | 0.09 | 1.46 (0.79 to 2.73) | 0.23 |
*Unadjusted ORs (95% CI) of tofacitinib versus tocilizumab were determined for each of the CDAI-based improvement measures according to single conditional logistic regression analyses. ORs (95% CIs) of tofacitinib versus tocilizumab were adjusted for concurrent MTX use and concurrent PSL use by conditional multivariable logistic regression analysis. Unadjusted and adjusted ORs (95% CIs) of confounder variables (MTX use and PSL use) for each of the CDAI-based improvement measures are shown in online supplemental tables 1and 2.
†Defined as achieving and maintaining ≥50% improvement of CDAI (CDAI50), ≥70% (CDAI70) and ≥85% (CDAI85) during the 12-month treatment.
‡Defined as CDAI reduction >12 for patients starting with a high CDAI and CDAI reduction >6 for those starting with a moderate CDAI at 12 months of treatment.
bDMARD, biological disease-modifying antirheumatic drug; CDAI, clinical disease activity index; MCID, minimal clinically important difference; MTX, methotrexate; PSL, prednisolone; RA, rheumatoid arthritis.